EPS growth is an important number as it indicates the future prospects of Cerus Corporation. It is typically displayed as a percentage and called the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 36.10 % over the last twelve months. Growth in EPS is an important measure of administration performance because it shows how much money Cerus Corporation is making for it’s investors or shareholders.
Cerus Corporation trades as part of the biotechnology industry and healthcare sector. The company CEO is William M. Greenman. Cerus Corp is a biomedical products company. It is engaged in developing and commercializing the INTERCEPT Blood System to enhance blood safety.
Previous Intraday Performance:
The CERS shares had a previous change of 0.96% which opened at 5.21 and closed at 5.25. It moved to an intraday high of 5.29 and a low of 5.16.
Business Wire: Cerus to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
Historical Performance:
Over the last five trading days, CERS shares returned -1.50% and in the past 30 trading days it returned -20.81%. Over three months, it changed -29.53%. In one year it has changed 35.66% and within that year its 52-week high was 8.05 and its 52-week low was 3.35. CERS stock is 56.72% above its 52 Week Low.
Our calculations result in a 200 day moving average of 6.27 and a 50 day moving average of 6.21. Right now, CERS stock is trading -16.24% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
Business Wire: Cerus to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum
Liquidity:
The company has a market cap of $712.4m with 135.7m shares outstanding and a float of 132.8m shares. Trading volume was 651,122 shares and has experienced an average volume of 926,194 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
Earnings:
The last annual reported EPS for Cerus Corporation was -0.56 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.11.
Below was the last reported quarterly earnings per share:
09-30-2018: -0.11
06-30-2018: -0.10
03-31-2018: -0.11
12-31-2017: -0.10
Indicators Also to Watch:
Based on the latest filings, there is 2.20% of insider ownership and 53.30% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.
I calculated the beta to be 1.51
Business Wire: Broadway Financial Corporation Announces Increased Profits for 3rd Quarter 2018
Fundamental Numbers:
Based on last reported financials, the company’s return on equity is -81.94%, return on assets is -40.85%, profit margin is -87.17%, price-to-sales is 11.64 and price-to-book is 7.76.
Company Score Card:
Results are out of six:
2 : Growth Expectations Result
5 : Financial Safety Result
0 : Past Performance Result
0 : Valuation Result
0 : Dividend Safety Result
1 : Overall Result
Related Tags: Biotechnology, CERS, Cerus Corporation, Healthcare
